Vestal Point Capital LP Acquires 12,677 Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

Vestal Point Capital LP increased its holdings in shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) by 11.3% during the third quarter, Holdings Channel.com reports. The firm owned 124,677 shares of the biotechnology company’s stock after buying an additional 12,677 shares during the period. Vestal Point Capital LP’s holdings in Atara Biotherapeutics were worth $1,014,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Atara Biotherapeutics in the 2nd quarter valued at $53,000. Cubist Systematic Strategies LLC purchased a new position in Atara Biotherapeutics in the second quarter valued at about $79,000. FMR LLC raised its holdings in Atara Biotherapeutics by 41.7% in the third quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock worth $204,000 after purchasing an additional 7,381 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its position in shares of Atara Biotherapeutics by 8,916.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 4,958,150 shares of the biotechnology company’s stock valued at $3,442,000 after buying an additional 4,903,159 shares during the last quarter. Institutional investors own 70.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Mizuho raised shares of Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and cut their price target for the stock from $25.00 to $18.00 in a report on Friday, August 16th. HC Wainwright restated a “neutral” rating on shares of Atara Biotherapeutics in a research note on Wednesday, August 21st. Finally, Canaccord Genuity Group increased their price target on Atara Biotherapeutics from $13.00 to $21.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $16.67.

Atara Biotherapeutics Trading Down 0.7 %

Shares of NASDAQ ATRA opened at $12.18 on Friday. Atara Biotherapeutics, Inc. has a 52 week low of $6.50 and a 52 week high of $39.50. The business’s 50 day moving average price is $9.54 and its 200 day moving average price is $10.03.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) EPS for the quarter, topping analysts’ consensus estimates of ($3.77) by $0.84. The company had revenue of $40.19 million during the quarter, compared to analysts’ expectations of $23.00 million. During the same quarter in the previous year, the company earned ($16.50) EPS. On average, sell-side analysts expect that Atara Biotherapeutics, Inc. will post -12.12 EPS for the current fiscal year.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.